{
    "xml": "<topic id=\"PHP18720\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/ruxolitinib\" basename=\"ruxolitinib\" title=\"RUXOLITINIB\">\n<title>RUXOLITINIB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1231\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/ruxolitinib\">Ruxolitinib</xref>\n</p>\n<data name=\"vtmid\">703779004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_208007314\" title=\"Protein kinase inhibitors\">Protein kinase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP73579\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/ruxolitinib\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Ruxolitinib is a selective inhibitor of the Janus-associated tyrosine kinases JAK1 and JAK2.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73566\" outputclass=\"indicationsAndDose\" rev=\"1.16\" parent=\"/drugs/ruxolitinib\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73584\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/ruxolitinib\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73597\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/ruxolitinib\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Assess risk of developing infection before treatment&#8212;do not initiate until active serious infections are resolved</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Tuberculosis</p>\n<p>Patients should be evaluated for latent and active tuberculosis before starting treatment and monitored for signs and symptoms of tuberculosis during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73562\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/ruxolitinib\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (ruxolitinib).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73540\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/ruxolitinib\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dizziness</ph>; <ph outputclass=\"sideEffect\">flatulence</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypercholesterolaemia</ph>; <ph outputclass=\"sideEffect\">weight gain</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Tuberculosis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">progressive multifocal leucoencephalopathy</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73557\" outputclass=\"pregnancy\" parent=\"/drugs/ruxolitinib\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73603\" outputclass=\"breastFeeding\" parent=\"/drugs/ruxolitinib\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73571\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ruxolitinib\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73547\" outputclass=\"renalImpairment\" parent=\"/drugs/ruxolitinib\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose in severe impairment (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73527\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ruxolitinib\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor full blood count (including differential white cell count) before treatment, then every 2&#8211;4 weeks until dose stabilised, then as clinically indicated.</p>\n<p>Monitor for infection during treatment.</p>\n<p>Monitor for symptoms of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological, cognitive or psychiatric signs or symptoms)&#8212;withhold treatment if suspected.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73511\" outputclass=\"nationalFunding\" rev=\"1.16\" parent=\"/drugs/ruxolitinib\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA289</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (June 2013)</p>\r\n<p>Ruxolitinib is <b>not </b>recommended for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA289\">www.nice.org.uk/TA289</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP18720-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ruxolitinib\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75580\" title=\"Tablet\" namespace=\"/drugs/ruxolitinib/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1231\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/ruxolitinib\" title=\"Ruxolitinib\" count=\"1\" rel=\"link\">Ruxolitinib</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75580\" namespace=\"/drugs/ruxolitinib/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP18720",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/ruxolitinib",
    "basename": "ruxolitinib",
    "title": "RUXOLITINIB",
    "interactants": [
        {
            "id": "bnf_int_1231",
            "label": "Ruxolitinib"
        }
    ],
    "vtmid": "703779004",
    "drugClassification": [
        "Protein kinase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Ruxolitinib is a selective inhibitor of the Janus-associated tyrosine kinases JAK1 and JAK2.",
                "html": "<p>Ruxolitinib is a selective inhibitor of the Janus-associated tyrosine kinases JAK1 and JAK2.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis",
                        "html": "Treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Assess risk of developing infection before treatment&#8212;do not initiate until active serious infections are resolved",
                "html": "Assess risk of developing infection before treatment&#8212;do not initiate until active serious infections are resolved"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Tuberculosis",
                "textContent": "Patients should be evaluated for latent and active tuberculosis before starting treatment and monitored for signs and symptoms of tuberculosis during treatment.",
                "html": "<p>Patients should be evaluated for latent and active tuberculosis before starting treatment and monitored for signs and symptoms of tuberculosis during treatment.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (ruxolitinib).",
                "html": "<p>Appendix 1 (ruxolitinib).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Dizziness",
                        "html": "Dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flatulence",
                        "html": "flatulence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypercholesterolaemia",
                        "html": "hypercholesterolaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight gain",
                        "html": "weight gain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Tuberculosis",
                        "html": "Tuberculosis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "progressive multifocal leucoencephalopathy",
                        "html": "progressive multifocal leucoencephalopathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies.",
                "html": "<p>Avoid&#8212;toxicity in <i>animal </i>studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose (consult product literature).",
                "html": "<p>Reduce dose (consult product literature).</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose in severe impairment (consult product literature).",
                "html": "<p>Reduce dose in severe impairment (consult product literature).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor full blood count (including differential white cell count) before treatment, then every 2&#8211;4 weeks until dose stabilised, then as clinically indicated.\n\nMonitor for infection during treatment.\n\nMonitor for symptoms of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological, cognitive or psychiatric signs or symptoms)&#8212;withhold treatment if suspected.",
                "html": "<p>Monitor full blood count (including differential white cell count) before treatment, then every 2&#8211;4 weeks until dose stabilised, then as clinically indicated.</p><p>Monitor for infection during treatment.</p><p>Monitor for symptoms of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological, cognitive or psychiatric signs or symptoms)&#8212;withhold treatment if suspected.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA289",
                        "label": "www.nice.org.uk/TA289"
                    }
                ],
                "fundingIdentifier": "NICE TA289",
                "textContent": "Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (June 2013) Ruxolitinib is not recommended for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.\n\nwww.nice.org.uk/TA289",
                "html": "<p outputclass=\"title\">Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (June 2013)</p> <p>Ruxolitinib is <b>not </b>recommended for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA289\">www.nice.org.uk/TA289</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75580",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1231",
                "label": "Ruxolitinib",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75580",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}